Yizhou Dong

Yizhou Dong

Yizhou Dong, PhD

Associate Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
434 Riffe Building
Email Address
Phone Number

Professional Interests

Professional Interests

Our research is devoted to drug discovery and delivery for the treatment of genetic disorders, infectious diseases, and cancers. Together with our collaborators, we integrate our specialty in pharmaceutics, pharmaceutical chemistry, biomedical engineering, materials formulation, and animal studies to design novel therapeutic medicines and uncover their mechanisms of actions. The ultimate goal is to translate our scientific results and technological inventions into more effective treatments and more fulfilling lives of all individuals.


  • 2014, Postdoctoral Fellow, Massachusetts Institute of Technology & Harvard Medical School
  • 2009, PhD, University of North Carolina at Chapel Hill, Medicinal and Pharmaceutical Chemistry
  • 2005, MS, Shanghai Institute of Organic Chemistry, Organic Chemistry
  • 2002, BS, Peking University, Pharmaceutical Science
  • Certificate in Applied Biostatistics, Harvard Medical School
  • Teaching Certificate, Teaching and Learning Laboratory Massachusetts Institute of Technology


  • NIGMS-Maximizing Investigators' Research Award (MIRA), 2016 - 2021
  • American Association of Pharmaceutical Scientists (AAPS) Emerging Leader Award 2020
  • Young Investigator Award by The Oligonucleotide Therapeutics Society 2018
  • Nano Research Young Innovator Awards (NR45) in NanoBiotech 2018
  • Young Innovator in Cellular and Molecular Bioengineering 2018
  • Ohio State Early Career Innovator of the Year 2018
  • Cellular and Molecular Bioengineering Conference Rising Star Award 2018
  • 40 Under 40 awards Columbus Business First 2017
  • New Investigator Grant, 2016 - 2017
  • Research Project Award, 2016 - 2017
  • Early Career Investigator Award, 2015 - 2017
  • ResearchReward, 2015 - 2016
  • Postdoctoral Fellow Awards, 2014
  • Ruth L. Kirschstein NRSA Postdoctoral Fellowship, 2013 - 2014
  • Postdoctoral Fellowship, 2013 - 2013
  • Graduate Student Award in Drug Design and Discovery, 2009 - 2009
  • The Rho Chi Pharmacy Honor Society, 2009 - 2009
  • Graduate Travel Award, 2009 - 2009
  • Beijing Outstanding Graduates, 2002 - 2002
  • Beijing Outstanding Undergraduate Students, 1999 - 1999
  • Fellowship of Peking University, 1998 - 2002

Journal Articles

Yan J, Kang DD, Dong Y. Harnessing lipid nanoparticles for efficient CRISPR delivery. Biomater Sci. 2021 Jun 11. doi: 10.1039/d1bm00537e. Epub ahead of print. PMID: 34115079.

Chan C, Du S, Dong Y, Cheng X. Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems. Curr Top Med Chem. 2021;21(2):92-114. doi: 10.2174/1568026620666201126162945. PMID: 33243123; PMCID: PMC8191596.

Zeng C, Hou X, Yan J, Zhang C, Li W, Zhao W, Du S, Dong Y. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo. Adv Mater. 2020 Oct;32(40):e2004452. doi: 10.1002/adma.202004452. Epub 2020 Sep 2. PMID: 32875709; PMCID: PMC8191860.

Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600. doi: 10.1016/j.apsb.2020.04.012. Epub 2020 Apr 24. PMID: 33088681; PMCID: PMC7564033.

Zhang X, Zhao W, Nguyen GN, Zhang C, Zeng C, Yan J, Du S, Hou X, Li W, Jiang J, Deng B, McComb DW, Dorkin R, Shah A, Barrera L, Gregoire F, Singh M, Chen D, Sabatino DE, Dong Y. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020 Aug 21;6(34):eabc2315. doi: 10.1126/sciadv.abc2315. PMID: 32937374; PMCID: PMC7442477.

Zhang S, Shrestha CL, Wisniewski BL, Pham H, Hou X, Li W, Dong Y, Kopp BT. Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages. Front Immunol. 2020 Aug 18;11:1871. doi: 10.3389/fimmu.2020.01871. PMID: 32973772; PMCID: PMC7461958.

Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW, Du S, Zhang C, Li W, Dong Y. Author Correction: Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020 Jul;15(7):615. doi: 10.1038/s41565-020-0675-8. Erratum for: Nat Nanotechnol. 2020 Jan;15(1):41-46. PMID: 32346117.

Zeng C, Zhang C, Walker PG, Dong Y. Formulation and Delivery Technologies for mRNA Vaccines. Curr Top Microbiol Immunol. 2020 Jun 2:10.1007/82_2020_217. doi: 10.1007/82_2020_217. Epub ahead of print. PMID: 32483657; PMCID: PMC8195316.

Li W, Chan C, Zeng C, Turk R, Behlke MA, Cheng X, Dong Y. Rational Design of Small Molecules to Enhance Genome Editing Efficiency by Selectively Targeting Distinct Functional States of CRISPR-Cas12a. Bioconjug Chem. 2020 Mar 18;31(3):542-546. doi: 10.1021/acs.bioconjchem.0c00062. Epub 2020 Mar 6. PMID: 32119776; PMCID: PMC8192075.

Zhao P, Hou X, Yan J, Du S, Xue Y, Li W, Xiang G, Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020 Mar 18;5(2):358-363. doi: 10.1016/j.bioactmat.2020.03.001. PMID: 32206737; PMCID: PMC7078456.

Li B, Yan J, Zhang Y, Li W, Zeng C, Zhao W, Hou X, Zhang C, Dong Y. CRISPR- Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by Synthetic Oligonucleotides. Mol Ther Nucleic Acids. 2020 Mar 6;19:1043-1052. doi: 10.1016/j.omtn.2019.12.038. Epub 2020 Jan 14. PMID: 32045875; PMCID: PMC7015830.

Guo S, Vieweger M, Zhang K, Yin H, Wang H, Li X, Li S, Hu S, Sparreboom A, Evers BM, Dong Y, Chiu W, Guo P. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nat Commun. 2020 Feb 20;11(1):972. doi: 10.1038/s41467-020-14780-5. PMID: 32080195; PMCID: PMC7033104.

Li B, Niu Y, Ji W, Dong Y. Strategies for the CRISPR-Based Therapeutics. Trends Pharmacol Sci. 2020 Jan;41(1):55-65. doi: 10.1016/j.tips.2019.11.006. Epub 2019 Dec 17. PMID: 31862124.

Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW, Du S, Zhang C, Li W, Dong Y. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020 Jan;15(1):41-46. doi: 10.1038/s41565-019-0600-1. Epub 2020 Jan 6. Erratum in: Nat Nanotechnol. 2020 Jul;15(7):615. PMID: 31907443; PMCID: PMC7181370.